| Dr Tandy Sutton Repass, MD | |
|
3475 Richmond Rd Ste 200, Lexington, KY 40509-2500 | |
| (859) 296-4400 | |
| Not Available |
| Full Name | Dr Tandy Sutton Repass |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 15 Years |
| Location | 3475 Richmond Rd Ste 200, Lexington, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043444219 | NPI | - | NPPES |
| 003894900 | Medicaid | FL |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| John L. Buker, M.d., Psc | 7113813932 | 7 |
News Archive
Elan Corporation, plc today announced that it has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes.
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.
Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with family histories of these cancers are even discussing genetic testing with their physicians or other health care providers.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
Bioheart, Inc. announced today that at the American Heart Association Annual Meeting, it finalized the formation of a working group. The group's focus is to advance a BRIDGE TO RECOVERY clinical trial, combining a left ventricle assist device (LVAD) and Bioheart's MyoCell adult muscle stem cell composition and Bioheart's MyoCath needle tipped catheter delivery system.
› Verified 5 days ago
| Entity Name | John L. Buker, M.d., Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114197803 PECOS PAC ID: 7113813932 Enrollment ID: O20040226000997 |
News Archive
Elan Corporation, plc today announced that it has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes.
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.
Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with family histories of these cancers are even discussing genetic testing with their physicians or other health care providers.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
Bioheart, Inc. announced today that at the American Heart Association Annual Meeting, it finalized the formation of a working group. The group's focus is to advance a BRIDGE TO RECOVERY clinical trial, combining a left ventricle assist device (LVAD) and Bioheart's MyoCell adult muscle stem cell composition and Bioheart's MyoCath needle tipped catheter delivery system.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tandy Sutton Repass, MD 3475 Richmond Rd Ste 200, Lexington, KY 40509-2500 Ph: (859) 296-4400 | Dr Tandy Sutton Repass, MD 3475 Richmond Rd Ste 200, Lexington, KY 40509-2500 Ph: (859) 296-4400 |
News Archive
Elan Corporation, plc today announced that it has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes.
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.
Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with family histories of these cancers are even discussing genetic testing with their physicians or other health care providers.
Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.
Bioheart, Inc. announced today that at the American Heart Association Annual Meeting, it finalized the formation of a working group. The group's focus is to advance a BRIDGE TO RECOVERY clinical trial, combining a left ventricle assist device (LVAD) and Bioheart's MyoCell adult muscle stem cell composition and Bioheart's MyoCath needle tipped catheter delivery system.
› Verified 5 days ago
Charlie Becknell, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 250 Fountain Ct, Lexington, KY 40509 Phone: 859-263-4444 Fax: 859-254-1814 | |
Leigh Ann Carter Beard, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 715 Shaker Dr Ste 132, Lexington, KY 40504 Phone: 859-288-5004 Fax: 859-288-5007 | |
Dr. Dana Black, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3475 Richmond Rd, Suite 200, Lexington, KY 40509 Phone: 859-296-4400 Fax: 859-296-4300 | |
Dr. Sean A Marzolf, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 250 Fountain Ct, Lexington, KY 40509 Phone: 859-263-4444 Fax: 859-263-6781 | |
Dr. Clifton Smith, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 177 Burt Rd, Lexington, KY 40503 Phone: 859-276-1511 Fax: 859-276-3373 | |
Deborah K Phillips, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4071 Tates Creek Centre Dr Ste 202, Lexington, KY 40517 Phone: 859-226-0206 |